Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8328636 | 0.97 | HTR1D (0.39) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| SCHEMBL22453893 | 0.86 | CYP3A4 (0.37) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| SCHEMBL18960495 | 0.81 | GABRA1 (0.45) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| SCHEMBL3212255 | 0.78 | RAPGEF4 (0.60) | RAPGEF4ALDH1A1 | |
| SCHEMBL1285327 | 0.77 | CYP3A4 (0.37) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| Hydrochloric Acid SCHEMBL2071013 | 0.76 | RAPGEF4 (0.57) | RAPGEF4ALDH1A1 | |
| SCHEMBL29021130 | 0.76 | HTR1D (0.41) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| SCHEMBL16172587 | 0.74 | HTR1D (0.40) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| SCHEMBL25787216 | 0.74 | HTR1D (0.40) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| SCHEMBL11982081 | 0.74 | RAPGEF4 (0.36) | RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397663-A1 | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-20170166599-A1 | METAL COMPLEX AND LIGHT EMITTING DEVICE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-15 | — | — | US | disclosed |
| EP-3168223-A1 | METAL COMPLEX AND LIGHT EMITTING ELEMENT USING SAME | Sumitomo Chemical Company, Limited (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2673260-B1 | GLUCAGON RECEPTOR MODULATOR | PFIZER (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-5968944-A | TREATING STRESS AND ANXIETY RELATED DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0674625-B1 | AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY | PFIZER (US) | 1997-12-10 | — | — | EP | disclosed |
| CN-1036456-C | Amino-substituted pyrazoles | — | 1997-11-19 | — | — | CN | disclosed |
| US-5668145-A | Amino-substituted pyrazoles having CRF antagonistic activity | PFIZER INC. (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0764153-A1 | SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995033727-A1 | SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| EP-0674625-A1 | AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| CN-1094038-A | The amino pyrazoles that replaces | PFIZER (US) | 1994-10-26 | — | — | CN | disclosed |
| WO-1994013644-A1 | AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166599-A1 | METAL COMPLEX AND LIGHT EMITTING DEVICE USING THE SAME | CRY1, AP2M1, CCNE2 | HTR1D 891/4885HTR1B 942/4885RAPGEF4 3549/4885 |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | HTR1D 782/4885HTR1B 296/4885RAPGEF4 466/4885 |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | HTR1D 782/4885HTR1B 296/4885RAPGEF4 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.